Carlo Croce, facing misconduct allegations, accuses former colleague of misconduct

Carlo Croce

Carlo Croce, a cancer researcher who has faced numerous research misconduct allegations, recently accused a former lab member of misconduct. Although an institutional probe did not support that allegation, Croce’s efforts have led to a retraction.

In November 2015, Croce and another cancer researcher at Ohio State University (OSU), Ramiro Garzon, contacted PLOS ONE, alleging that the paper’s corresponding author, Stefan Costinean, published data without their knowledge or permission and without “accurately acknowledging their contributions to the research.” Although the PLOS ONE paper mentioned Croce’s and Garzon’s contributions in the acknowledgements section, the two were not included as co-authors. We have obtained a copy of the report describing OSU’s preliminary probe; it did not find evidence of misconduct, but recommended the paper be retracted for using data without permission. Although Costinean disagreed, the journal has since retracted the paper.

Croce has been on the other side of this process: Seven of his papers have been retracted for issues including manipulation and duplication. After a New York Times article, published in March, explored misconduct allegations against Croce, OSU said the university is “instituting an independent external review.” Croce is currently suing the New York Times, alleging that the newspaper defamed him in the story.

Continue reading Carlo Croce, facing misconduct allegations, accuses former colleague of misconduct

Researchers ask to retract cancer paper five days after it’s flagged by journal

Researchers from the University of Kansas asked to retract their paper only days after the journal issued an expression of concern related to some of the images.

The retraction notice marks the close of an episode that started in June, but it doesn’t provide much closure: Figures in the paper apparently do not match primary data, but there’s no hint as to how that happened.

In a statement sent to JCS — just five days after the expression of concern came out — last author Kristi Neufeld, a cancer biologist at KU, wrote: Continue reading Researchers ask to retract cancer paper five days after it’s flagged by journal

More duplications for researcher accused of misconduct in lawsuit

Despite losing a lawsuit against his former mentor, a researcher hasn’t stopped his efforts to discredit his mentor’s work. These efforts have led to new editorial notices — including, most recently, a correction and expression of concern for one paper by a former colleague, who wasn’t even the subject of the lawsuit.

In the 2014 suit, former Brown University postdoc Andrew Mallon said research misconduct by John Marshall — his lab director and former business partner– tainted a 2013 paper published in PLoS Biology. Though the case failed to trigger the retraction Mallon sought, it put his concerns into the public record; the text of the lawsuit includes an accusation of misconduct against Cong CaoMarshall’s former mentee and the first author of that 2013 paper.

Mallon has since contacted journals to raise concerns about papers by Cao, and two journals have taken action. The most recent move: On Aug. 10, the Biochemical Journal did something we don’t see very often — it issued both a correction and an expression of concern (EoC) for one of Cao’s papers: “EGFR-mediated expression of aquaporin-3 is involved in human skin fibroblast migration,” originally published Nov. 14, 2006. Continue reading More duplications for researcher accused of misconduct in lawsuit

Caught Our Notice: Concerns about image in 2008 paper prompt editorial notice

Via Wikimedia

Title: Characterization of a novel epigenetically-silenced, growth-suppressive gene, ADAMTS9, and its association with lymph node metastases in nasopharyngeal carcinoma

What caught our attention: One year ago, a PubPeer user suggested an image from a 2008 paper looked similar to one from another paper. After the authors stated their belief in the soundness of the image, without providing the originals, the journal issued only an Expression of Concern for the paper. Some journals have issued retractions for lack of original data, some have issued corrections, and even fewer have published editorial notices. Expressions of concern usually indicate that some type of final resolution will be announced, but in reality, a significant proportion remain unresolved for years. Based on the wording of this notice, it may be around for a while. Continue reading Caught Our Notice: Concerns about image in 2008 paper prompt editorial notice

Widely used U.S. government database delists cancer journal

The U.S. government biomedical research database MEDLINE no longer includes a cancer journal with a storied past.

Starting August 2017, researchers looking up journals indexed in MEDLINE (which is accessed via PubMed) could no longer find new articles published by Oncotarget, once included on the now-defunct list of possibly predatory journals compiled by librarian Jeffrey Beall.

Joyce Backus, the National Library of Medicine’s Associate Director for Library Operations, declined to say why Oncotarget had been deselected from MEDLINE:

Continue reading Widely used U.S. government database delists cancer journal

Unnamed institution makes baffling retraction requests, journals comply

Two journals are retracting papers published by researchers affiliated with Children’s Hospital Los Angeles (CHLA).

To be frank, we’re baffled by most of this story. The retraction notices say “the institution” requested the retractions, but don’t name it; the first and last authors are also affiliated with the University of Southern California, as well as CHLA. Neither journal will say which institution sent the request, and USC and CHLA have each declined to comment on the retractions.

Here’s what we do know: Continue reading Unnamed institution makes baffling retraction requests, journals comply

Caught Our Notice: An “absolutely perfect retraction”

Via Wikimedia

When Retraction Watch began in 2010, our co-founders Ivan Oransky and Adam Marcus quickly realized they couldn’t keep up with the hundreds of retractions that appeared each year.  And the problem has only gotten worse — although we’ve added staff, the number of retractions issued each year has increased dramatically. According to our growing database, more than 1300 retractions were issued last year (and that doesn’t include expressions of concern and errata). So to get new notices in front of readers more quickly, we’ve started a new feature called “Caught our Notice,” where we highlight a recent notice that stood out from the others. If you have any information about what happened, feel free to contact us at [email protected].

Title: Skeletal muscle-specific CPT1 deficiency elevates lipotoxic intermediates but preserves insulin sensitivity

What caught our attention:  Continue reading Caught Our Notice: An “absolutely perfect retraction”

Caught Our Notice: Investigation finds “accidental mistakes” in PNAS stem cell paper

Via Wikimedia

When Retraction Watch began in 2010, our co-founders Ivan Oransky and Adam Marcus quickly realized they couldn’t keep up with the hundreds of retractions that appeared each year.  And the problem has only gotten worse — although we’ve added staff, the number of retractions issued each year has increased dramatically. According to our growing database, just shy of 1,000 retractions were issued last year (and that doesn’t include expressions of concern and errata). So to get new notices in front of readers more quickly, we’ve started a new feature called “Caught our Notice,” where we highlight a recent notice that stood out from the others. If you have any information about what happened, feel free to contact us at [email protected].

Title: Combined hydrogels that switch human pluripotent stem cells from self-renewal to differentiation 

What caught our attention: Continue reading Caught Our Notice: Investigation finds “accidental mistakes” in PNAS stem cell paper

Dispute over author order torpedoes paper on syndrome linked to autism

At least one disgruntled co-author has triggered the retraction of a paper presenting a novel approach to treating a rare, genetically inherited condition.

The paper concerned research on Fragile X syndrome (FXS), characterized by both intellectual and physical abnormalities, which is linked autism. A compound that passed through phase 2 clinical trials in October 2015 appeared to partially treat FXS in mice in the study, published earlier this year.

The journal’s notice says the paper was retracted over a dispute among authors about the order in which they are listed on the paper: Continue reading Dispute over author order torpedoes paper on syndrome linked to autism

A journal printed a sharp critique of a paper it had published. If only it had checked with the authors first.

In 2016, researchers published a paper showing that an RNA molecule may be overactive in breast tumor tissue. But after reading the paper, three biologists believed the data supported the opposite conclusion.

What happened after that is a tale of misunderstandings and unnecessarily bruised feelings. We’ve seen plenty of cases where researchers ignore criticism, which at first glance seemed to be the case here. But upon closer inspection, it wasn’t. Continue reading A journal printed a sharp critique of a paper it had published. If only it had checked with the authors first.